Founded by Dheeraj Jain, the brand ‘Redcliffe Labs’ was coined in the year 2021 when it ventured into routine diagnostics services with the foundation pillar to bring affordable & high-quality diagnostic services with ease of booking and home collection convenience, using the most advanced technology and processes, to people across the Indian subcontinent. Offering more than 3600+ tests for all age groups covering all major diseases with accurate results and fast turnaround time, Redcliffe Labs aims to revolutionize the healthcare industry in India.
Before that, it operated under the brand name Redcliffe Lifesciences, which was started in 2018 with a focus on specialized testing in reproductive care, oncology, rare diseases, and research. Redcliffe Labs’ expansion into routine diagnostics services marked a significant milestone in its journey to provide comprehensive healthcare solutions to a broader audience.
Redcliffe Labs services are available in 220+ cities across India through a wide network of on-ground phlebotomists fleet, 80+ labs, and 2000+ collection centers. All labs and collection centers follow the highest quality standards from day one to provide affordable yet high-end quality diagnostic services to customers.
With a track record of successfully serving 4M+ patients to date, Redcliffe Labs envisions becoming the most trusted and affordable diagnostics platform for Bharat, empowering health and impacting lives positively.
Technological Innovations and Quality Initiatives
In 2023, Redcliffe Labs made significant technological advancements and innovations aimed at improving the quality of services and enhancing the overall customer experience. Some of these developments include:
- Clinical Decision Support (CDS) System: Redcliffe Labs introduced the ‘AI-based’ Abbott AlinIQ Clinical Decision Support (CDS) System, making it the first diagnostic provider in India to adopt such a transformative technology. The CDS system utilizes advanced data interpretation technology to deliver patient-specific content and intelligent insights. It offers supportive guidance and protocol reinforcement to improve patient care by enhancing clinical management. This system is clinician-driven and provides customized clinical insights based on patient demographics, historical data, and clinical notes. The AI-enabled CDS algorithm automates the decision-making process for individual patient cases, reflecting scientific interpretations driven by clinical recommendations.
- Implementation of Six Sigma Processes: Redcliffe Labs, under the guidance of Dr. Sohini Sengupta, its Medical Director, has implemented Six Sigma processes to ensure high-quality and accurate test results. Six Sigma is a data-driven process improvement methodology that aims to achieve operational excellence by minimizing errors and defects in processes. By following Six Sigma principles, Redcliffe Labs aims to achieve ‘world-class’ performance, with a focus on reducing the Defects Per Million Opportunities (DPMO) metric to less than 3.4. This approach is particularly beneficial in a high-volume clinical laboratory setting, where thousands of test results are generated daily, and adherence to quality specifications is critical.
These innovations demonstrate Redcliffe Labs’ commitment to leveraging technology and adopting best practices to deliver superior healthcare services and improve patient outcomes. Through the implementation of advanced systems like the CDS and adherence to quality improvement methodologies like Six Sigma, Redcliffe Labs continues to set new standards in the healthcare and health tech industry in India.
Driving Change
Dheeraj embarked on a mission in 2017 to revolutionize healthcare in India by providing affordable, accessible, and advanced diagnostic services for a Healthier Bharat. His journey towards this goal began with a strong background in management technology consulting in London, followed by nine years of valuable experience at Nokia, where he gained insights across various functions. His MBA from Cass Business School further honed his skills and knowledge.
In 2011, Dheeraj transitioned from Nokia to the leveraged buyout market, where he played a significant role in Indian mergers and acquisitions. Returning to India, he co-founded successful startups like Candes and The Man Company, with a focus on impactful ventures such as PeeSafe for women’s health.
Recognized as one of the most prolific angel investors, Dheeraj continued to foster innovation in the startup ecosystem. In 2017, his vision culminated in the founding of Redcliffe Labs, a platform dedicated to providing affordable and technologically advanced diagnostics to reshape healthcare in India.
With Dheeraj’s vision, the unwavering dedication of stakeholders, and the commitment of co-founders, Redcliffe Labs emerged as a beacon of hope, promising a healthier future for the nation. Dheeraj’s journey continues to be driven by a passion for creating impactful change in healthcare and improving the lives of people across India.
Impact on India’s Healthcare Landscape
Redcliffe Labs has been instrumental in improving the healthcare landscape of India by focusing on four key pillars: Quality, Convenience, Affordability, and Accessibility. In a country where nearly 5.8 million people die due to Non-Communicable Diseases (NCDs) every year, Redcliffe Labs has played a crucial role in raising awareness about preventive health checkups and empowering individuals to make informed decisions about their health.
With initiatives such as online campaigns and offline camps, Redcliffe Labs has successfully encouraged people to prioritize their health and undergo regular health checkups. By providing convenient access to high-quality diagnostic services at affordable prices, Redcliffe Labs has helped individuals identify health risks early, enabling timely interventions and preventive measures.
Addressing the growing concern of NCDs, including heart diseases, stroke, lung diseases, cancer, and diabetes, Redcliffe Labs is dedicated to promoting a Healthier Bharat. Through its commitment to quality, convenience, affordability, and accessibility, Redcliffe Labs continues to make significant strides in improving healthcare outcomes and enhancing the overall well-being of the Indian population.
Balancing Quality and Affordability
Redcliffe Labs faces a significant challenge in the healthcare sector, particularly in diagnostics, regarding the pricing and quality of health checkups. Variability in pricing and ensuring accurate reports are crucial for effective treatment. Addressing these challenges nationwide requires balancing high standards with affordability. Redcliffe Labs tackles this through technology integration, omnichannel streamlining, and unified software for quality analysis. This approach ensures precision without inflating costs, aiming to enhance customer experience and healthcare accessibility across India.
Providing Uninterrupted Services Amidst the Pandemic
Starting services during the pandemic proved advantageous for Redcliffe Labs, as all team members, including field personnel like riders and phlebotomists, received tailored training. Consequently, ensuring safety for both the team and customers, whether during or after the pandemic, isn’t a challenge. Redcliffe Labs remains steadfast in delivering uninterrupted services, reaffirming its commitment to customer care and operational excellence.
Democratize Healthcare Across India
Redcliffe Labs has established a widespread presence across India, spanning over 220 cities with 2000+ collection centers and 80+ labs. The ambitious goal for 2030 is to serve 500 million people nationwide. Notably, the company prioritizes expansion in tier 2 and tier 3 cities, aiming to bridge healthcare disparities. Even in regions with limited digital engagement, Redcliffe Labs actively reaches out, organizing over 1500 health camps weekly, catering to the healthcare needs of over 2 lakh+ patients. This concerted effort reflects the company’s commitment to making healthcare accessible to all, irrespective of geographical or digital barriers.
Empowering Wellness
There is an urgent need to address the high risk of Non-Communicable Diseases (NCDs) in India, with 1 in every 4 individuals succumbing to NCDs before the age of 70. To improve India’s healthcare scenario, Redcliffe Labs made a strategic shift towards wellness-focused approaches rather than solely addressing illness. It actively contributes to this goal by promoting preventive healthcare checkups and offering high-quality diagnostics at affordable rates.
A study presented in the UN General Assembly in September 2023 underscores the economic impact of Redcliffe Labs’ diagnostics in India. The study indicates that Redcliffe’s tests deliver approximately $400 million in economic savings by offering cost-effective solutions for preventing cardiovascular disease and diabetes. Specifically, Redcliffe’s tests are found to be up to 8 times more cost-effective than national treatment coverage for cardiovascular disease and less than 2/3 the cost of comparable screening and telemedicine interventions for diabetes. This highlights the significant contribution of Redcliffe Labs towards reducing the burden of NCDs and promoting a healthier Bharat.
Read More: Click Here
